Pei Zhang

机构：Bengbu Medical College, Chinese PLA General Hospital, Nanjing Medical University · ORCID：0009-0003-4394-970X

发表论文 6 篇 · 总被引 44 次 · h-index 3

代表论文

• Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
• Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective (2019 · Clinical & Translational Oncology · 被引 14)
• The role of cGAS-STING pathway in the development of radiation-induced lung injury (2025 · Journal of Cancer Research and Clinical Oncology · 被引 9)
• pH and Glutathione-Responsive Sequentially Releasing Hydroxyl Radical and Hydrogen Sulfide Nanozyme for Effective Wound Infection Treatment via Bimodal Chemodynamic-Gas Therapy (2025 · ACS Applied Nano Materials · 被引 2)
• Halofuginone targets Serine/Glycine synthesis to reverse epidermal growth factor receptor Tyrosine Kinase inhibitor resistance in lung adenocarcinoma (2025 · Phytomedicine · 被引 2)
• Characteristics of indications, clinical trial evidence, clinical benefits and the costs of price-negotiated multi-indication drugs for solid tumours in China (2025 · Journal of Global Health · 被引 1)